Skip to main content
. Author manuscript; available in PMC: 2023 Sep 1.
Published in final edited form as: Cancer Discov. 2023 Mar 1;13(3):580–597. doi: 10.1158/2159-8290.CD-22-0964

Fig. 1. Design of phase-1 clinical trial evaluating CD19/CD20 bispecific CAR-T cell therapy (CART19/20) in patients with non-Hodgkin lymphoma, chronic lymphocytic leukemia, and small lymphocytic lymphoma.

Fig. 1.

(A) Schematic of CD19/CD20 bispecific CAR construct. (B) Schematic of phase-1 dose escalation trial design. (C) Consolidated Standards of Reporting Trials (CONSORT) diagram of CART19/20 trial.